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Ovarian carcinomas are associated with an extremely poor prognosis, resulting in a 5-year survival of 30% for 
advanced-stage disease. Unlike other malignancies, no significant improvement in disease management and 
overall survival has been achieved in the past three decades, underlining the urgent need of new therapeutic 
opportunities. The cooperation of Bcl-xL and Mcl-1 is required to protect ovarian cancer cells against apoptosis. 
Given that miRNAs target the expression of several genes, in a coordinated manner, often at the nodes of 
important regulatory pathways, we hypothesized that among miRNAs able to kill chemoresistant ovarian cancer 
cell lines some may target both Bcl-xL and Mcl-1. Recently, we demonstrated that miR-491-5p induces apoptosis 
in several ovarian cancer cells by inhibiting directly Bcl-xL and indirectly Mcl-1 through the targeting of EGFR 
leading to BIM activation. Interestingly, the apoptotic effect of miR-491-5p could be mimicked by a combining 
an EGFR inhibitor with a BH3-mimetic molecule (two drugs already used in clinical practice). In addition, the 
knowledge of the precise molecular effect of miR-491-5p provided ways to identify downstream genetic 
alterations impeding the pro-apoptotic effect of miR-491-5p in another cellular context. The resistance to this 
combination treatment was finally counteracted by associating pharmacological molecules affecting the involved 
pathways at pertinent levels. Altogether, our work highlights the potential of phenotype-based miRNA screening 
approaches to decipher, in the absence of a preconceived idea, new relevant therapeutic targets harboring 
synthetic lethal interactions to finally propose new rationale drug combinations. 
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Introduction 
Ovarian cancer is the most aggressive gynaecological 
malignancy [1]. The yet unpredictable recurrence observed in 
more than 75% of the ovarian carcinoma patients, associated 
to the fact that the relapsed disease generally becomes 
unresponsive to conventional chemotherapy 
(carboplatin/paclitaxel), is responsible for the poor overall 
survival rate. More than 230,000 new cases are diagnosed 
each year worldwide, at a late dissemination stage in the 
majority of cases, leading to the death of about 140,000 
women [2]. Despite advances in surgery and chemotherapy 
practices, the ultimate rate of cure has not been strongly 
impacted during the past three decades, the 
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mortality/incidence ratio thus remaining dramatically 
elevated. Improved ovarian cancer therapeutic care needs the 
development of both improved early detection methods and 
innovative therapeutics susceptible to overcome 
chemoresistance. 
More and more efforts are made to develop targeted 
therapies, specifically dedicated to the treatment of patients 
with identified genetic alterations, but ovarian cancers 
therapeutic care lags behind other cancer types in 
incorporating such therapies into standard treatment. The 
angiogenesis inhibitor bevacizumab (Avastin®) was the first 
”targeted therapy” which has been introduced in clinical 
practice and was shown to only modestly increase 
progression-free survival (PFS) [3]. In addition, guidelines for 
the therapeutic use of bevacizumab in ovarian cancer differ 
worldwide. For example, the European Medicines Agency 
(EMA) has approved bevacizumab in combination with 
carboplatin and paclitaxel as first-line therapy [4, 5] whereas 
the Food and Drug Administration (FDA) has approved 
bevacizumab only for use in combination with other 
treatments for women with recurrent and platinum-resistant 
ovarian cancer [6]. Very recently, the PARP inhibitor, 
Olaparib (Lynparza™) has been approved for monotherapy 
in the treatment of advanced ovarian cancer. However, its 
recommendation is limited to patients harboring BRCA1 or 
BRCA2 gene mutations (10-15% of cases) who have 
previously received three or more lines of therapy [7]. Others 
molecular targeted therapies are under further evaluation in 
ongoing clinical trials. The most suitable strategies for these 
innovative approaches will thus be defined in various settings 
[first-line, relapse (platinum-sensitive and resistant)] in a 
near future [8]. Moreover, the definition of interaction 
between these agents and various pathways as well as the 
associated predictive markers is a major objective for safe 
and efficient treatment. 
However, while the initial results of targeted therapies in 
laboratory and clinic have proved promising in ovarian 
cancer, and globally in the field of oncology, they also 
provided researchers and clinicians with a cautionary tale. 
Indeed, in most of the case, the redundancy of survival 
pathways, the cross-talk and feedback loops which sustain 
tumor cells survival are often at the origin of tumor escape 
from current targeted therapies. In addition, the emergence of 
alterations and mutations in the targeted pathways can result 
in the appearance of resistance phenotypes. Perhaps, using 
combination of targeted therapies will limit the probability of 
the development of resistance. The detailed characterization 
of the pathways involved in ovarian cancer cells survival, 
chemoresistance and response to treatments is then of 
outmost importance to design new innovative treatment 
options.  
In this context, microRNAs (miRNAs) represent an 
interesting area to explore. Indeed, miRNAs are a class of 
endogenous small non-coding RNAs and they act through 
imperfect sequence complementarity by binding in the 3′ 
untranslated region (UTR) of target messenger RNAs 
(mRNAs), and negatively regulate mRNA translation and 
stability [9]. Now there are over 2,500 potential human 
miRNAs recorded in miRBase (version 21, June 2014), and 
it is predicted that more than 60% of protein coding genes 
could be targeted by miRNAs. Consequently, it is not 
surprising that miRNAs have been found to play a crucial 
role in all basic biological processes and that their 
dysregulation is implicated in the development and 
progression of cancer, including ovarian carcinoma [10]. 
Importantly, one miRNA could target several hundreds of 
target mRNAs, and one transcript can be targeted by multiple 
miRNAs, leading to the formation of complex regulatory 
networks. Moreover, the most remarkable feature of 
miRNAs is that they often target proteins at the nodes of 
important regulatory pathways, opening new avenues in the 
perspective of drug target identification. 
miRNA as a tool to identify synthetic lethality 
Hallmarks of cancer have underlined the ability of tumor 
cells to escape from apoptosis as a major contributor of drug 
resistance and tumor progression [11]. Cancer cells often 
harbor alterations in the expression and activity of BCL-2 
family members leading to an increase in the apoptotic 
threshold. As a consequence, inhibition of the expression 
and/or activity of anti-apoptotic members of BCL-2 family 
represent an attractive way to selectively kill cancer cells. In 
ovarian carcinoma, Bcl-xL and Mcl-1 cooperating to protect 
ovarian cancer cells from cell death against apoptosis, their 
simultaneous inhibition is required to trigger apoptosis in 
chemoresistant ovarian cancer cell lines (IGROV1-R10 and 
SKOV3) [12, 13]. Postulating that miRNAs may coherently 
modulate genes involved in networks regulating apoptosis, 
we hypothesize that among miRNAs able to kill the 
chemoresistant ovarian cancer cell lines some may target 
both Bcl-xL and Mcl-1 [14]. 
Using in silico miRNA targets prediction algorithms 
together with functional studies, we tried to identify 
miRNA(s) that could induce apoptosis in ovarian cancer cells 
by targeting directly Bcl-xL and Mcl-1. Among the 11 
putative miRNAs identified by our approach, some 
down-regulated either Bcl-xL or Mcl-1, but none was shown 
to decrease both in our cellular models. However, the 
transfection of one miRNA, miR-491-5p, was found to 
induce apoptosis in IGROV1-R10 cells. We next 
demonstrated that Bcl-xL is a direct target of miR-491-5p as 
previously demonstrated by others in different cellular 
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contexts [15-17]. Whereas previous observation showed that a 
siRNA targeting Bcl-xL induces only a mild apoptotic effect, 
miR-491-5p induces a drastic cell death in IGROV1-R10 
cells, suggesting that other targets, either with direct/indirect 
or without relations with Mcl-1, may be involved in 
miR-491-5p mediated cell death.  
miR-491-5p exerts its cytotoxic effect by inhibiting 
directly Bcl-xL and indirectly Mcl-1 through the 
targeting of EGFR leading to BIM activation 
We demonstrated that the apoptotic effect of miR-491-5p 
is related on one hand to the down-regulation of Bcl-xL 
(direct effect) and on the other hand to the indirect inhibition 
of Mcl-1 activity. Indeed, miR-491-5p was shown to 
decreases directly EGFR expression which diminishes 
subsequently activation of both AKT and MAPK pathways 
leading to the BH3-only protein BIM induction and 
dephosphorylation, allowing finally the inhibition of Mcl-1 
activity and possibly direct activation of BAX/BAK (Figure 
1a). Of note, this study demonstrated, for the first time, that 
EGFR is a direct target of miR-491-5p in ovarian cancer 
cells. Although our target-driven approach did not lead to the 
identification of miRNA with direct effect on both Bcl-xL 
and Mcl-1, an interesting learning is the identification of the 
pathways involved in the death phenotype in response to 
miR-491-5p. Another study used a miRNA screen to identify 
miRNAs able to down-regulate Mcl-1, a determinant of 
response to a BH3-mimetic molecule (ABT-263). In 
HCT-116 cells, the authors identified several miRNAs able 
to trigger cell death but Mcl-1 down-regulation was not a 
direct effect for several of the miRNAs identified [18], 
paralleling our observations that a phenotype instead of a 
target-directed approach could be more efficient in 
characterizing the determinants of cancer cells survival. 
Figure 1. Potential of miRNA functional studies to decipher cell signalling pathways involved 
in cell survival to propose the rationale design of new strategies based on pharmacological 
combinations. (a) miR-491-5p induces apoptosis in ovarian cancer cells by inhibiting Bcl-xL and by 
targeting EGFR leading to BIM activation and subsequent Mcl-1 inhibition and possibly BAX/BAK 
activation. (b) The effect of miR-491-5p can be mimicked by a combination therapy of an EGFR 
inhibitor with a BH3-mimetic molecule. 
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Toward a phenotype-based consideration of miRNA 
effects 
One can hypothesize that screening of individual miRNAs 
against the induction of a specific phenotype (including cell 
death) might allow the identification of molecular 
determinants sustaining this phenotype, and thus of potential 
pharmacological targets. This requires miRNA to be 
implicated in coordinated regulation of gene networks as 
supported by several reports. For example, miRNAs may 
regulate proteins in the same complex, in the same signalling 
pathway or in the same biological function. A first 
experimental demonstration was provided by Linsley et al. 
[19]. Using miRNA transfection in DICER-deficient cell lines 
followed by comparative gene expression profiling, they 
showed that miR-16 affects many targets that function in a 
coordinated manner to regulate the G0/G1 to S cell cycle 
transition. Accordingly, simultaneous siRNA-mediated 
down-regulation of several miR-16 targets did block cell 
cycle progression in more efficient way than the silencing of 
individual miR-16 targets. In another study, the 
consequences on global gene expression pattern of the 
transfection of two individual miRNA, miR-7 and miR-128, 
in an ovarian cancer cell line, were monitored by microarrays 
and qPCR [20]. Modifications of gene expression were not 
random, and functional pathway analysis showed that genes 
modulated by miR-7 and miR-128 transfections were 
predominantly involved in distinct regulatory pathways: cell 
adhesion, EMT and development for miR-7, cell cycle 
regulation for miR-128. Experiments on cell adhesion and 
cell cycle gave results consistent with those predictions. 
Interestingly, functional and binding interaction network 
analysis suggested that transfection of individual miRNA, by 
impacting the regulation of hub genes (often directly), may 
indirectly affect the expression of a large number of 
downstream genes, and thus trigger cascades of coherent 
regulatory changes. Further evidence that miRNAs regulate 
functionally related genes within distinct networks has been 
reviewed recently [21]. A study integrating publicly available 
mRNA expression data from numerous cellular systems and 
tissues was able to establish co-expression clusters among 
predicted targets of individual human miRNA, reinforcing 
the hypothesis that the targets of a given miRNA belong to 
the same gene regulatory network [22]. A statistical analysis 
of enrichment of miRNA-targeting signatures in functionally 
annotated gene sets compared to random gene sets provided 
evidences that many miRNAs coordinately regulate several 
components of pathways. Some miRNAs can also function in 
multiple canonical pathways and mediate crosstalk between 
these pathways, to coordinately regulate cellular functions 
[23]. Otherwise, screening the effects of miRNA mimics on 
the viability of isogenic KRAS-wild type and KRAS-mutant 
colorectal cancer cell lines led to the identification of 
miR-126, which specifically reduced the growth of multiple 
KRAS-mutant cell lines, and inhibited clonogenicity and 
tumorigenicity. This selective effect, and the reduced 
expression of miR-126 in colorectal tumor with mutant 
KRAS as compared to wild type, led to the hypothesis that 
miR-126 regulates a coherent gene network that is required 
for the viability of KRAS-mutant cells. This postulated that 
synthetic lethal interaction between miR-126 target genes 
and mutant KRAS was compatible with the fact that 
transcriptome profiling failed to identify genes 
down-regulated by miR-126 only in KRAS-WT or 
KRAS-mutant cells. By analyzing the overlap between 
miR-126 targets with previously characterized synthetic 
lethal genes in KRAS-mutant cells, the authors identified that 
a subset of miR-126 regulated genes was required for the 
survival of KRAS mutant cells. SiRNA-down-regulation of 
individual miR-126 targets was less efficient than miR-126 
to decrease the clonogenicity of KRAS-mutant cells [24]. This 
work, in addition to the study by Lam et al. [18] and our 
recent work suggests that a phenotype- instead of a 
target-orientated strategy could prove itself successful to 
identify contextual synthetic lethal interactions. The intrinsic 
capacity of miRNAs to modulate the expression of a network 
of target genes in a comprehensive way to trigger a specific 
phenotype makes them very good candidates for a 
screening-based approach. This way, it would be possible to 
bring out relevant target associations harboring a synthetic 
lethal phenotype, in the absence of a preconceived idea about 
the targets.  
Using a “death” phenotype triggered by a miRNA to 
characterize synthetic lethality  
The characterization of the precise pathways regulated by 
a miRNA of interest can be achieved through the 
identification of its direct targets. To this end, different 
biochemical strategies based on co-precipitation of RNA 
with Ago proteins and/or a specific miRNA have been 
described [25]. For example, the transfection of a biotinylated 
miRNA and subsequent streptavidin based purification of 
direct targets have been successfully used to identify new 
direct targets of miR-34a [26]. Moreover, integration of 
information relative both to direct targets of a miRNA and to 
perturbation induced by a miRNA at transcriptomic and 
proteomic levels would allow the precise characterization of 
the pathways involved in a death phenotype, and thus 
provide opportunities for combinatory treatments. According 
to this strategy, our laboratory has performed a miRNA 
screen on several chemoresistant ovarian cancer cell lines, 
which identified several miRNAs able to trigger cell death 
(unpublished observations); the precise characterization of 
the pathways involved is currently under investigation.  
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Two possibilities exist with the identification of several 
miRNAs presenting a death phenotype in a given context 
(e.g. a specific cell line): (i) these miRNAs share an effect on 
identical pathways – although possibly at different levels, or 
(ii) they target different pathways. We hypothesize that these 
two options will appear to be true to some extent. Moreover, 
the combinatory aspect of the approach we present might 
identify targets within the network of a single miRNA whose 
individual regulation is harmless to cancer cells, and thus not 
yet identified as critical for their survival.  
Context dependence of the synthetic lethality revealed by 
the miR-491-5p: a problem or a source for tailoring new 
combinatorial therapeutics? 
It is worth noting that a given combinatory approach will 
not be effective in every cellular context. Screening for 
miRNA mediated-toxicity towards ovarian cancer cells 
cannot be tested on an individual basis in patient’s biopsies. 
However, the choice of several cell lines representative of 
ovarian cancer subtypes diversity will provide more 
combination options; it will reveal as well the extent of 
sensibility to a given combination among a range of ovarian 
cancer subtypes. A miRNA may have the same targets in 
different cellular contexts without inducing the same 
phenotype because of specific alterations in the 
involved-pathways. Intervention at different levels in these 
pathways can provide means to recover the phenotypic 
effect. As an example, we could evidence that miR-491-5p 
has a differential effect in SKOV3 cells without inducing 
apoptosis. Intriguingly, miR-491-5p decreases both Bcl-xL 
and EGFR expression similarly to the observation made in 
IGROV1-R10 cells but fails to inhibit both AKT and MAPK 
signaling and do not induce BIM in SKOV3 cells. These 
observations allowed us to hypothesize that BIM degradation 
was induced by a continuous activation of AKT and MAPK 
pathways downstream of EGFR. Indeed, we noticed that in 
SKOV3 cells ERK is more strongly activated than in 
IGROV1-R10 cell line. In addition, SKOV3 cells are 
characterized by an activating mutation (H1047R) in the 
PIK3CA gene, leading to continuous phosphorylation of 
AKT. Importantly, the use of specific inhibitors of AKT and 
MAPK pathways led to BIM dephosphorylation and induced 
apoptosis in SKOV3 cells with a siRNA targeting Bcl-xL. 
This observation demonstrated that the precise 
characterization of pathways involved in miRNA-induced 
phenotype can provide the opportunity to counteract context 
dependent resistance. 
Opportunities for therapeutic interventions based on 
miRNA biology 
It is now well established that there is substantial interest 
in exploiting miRNAs for therapeutic applications. However, 
most of studies were focused on the fact that miRNAs, 
themselves, could be considered as therapeutic agent 
(replenishing tumor suppressor miRNAs) or therapeutic 
target (silencing an oncomiR). For instance, restoration of 
miRNA levels can be achieved with ‘miRNA mimics’ or 
miRNA-expressing plasmids whereas miRNA knockdown is 
reached using chemically modified 
antisense-oligonucleotides [27]. Notably, one miRNA-based 
cancer therapy (MRX34, a liposome-based miR-34 mimic) 
has recently entered a Phase I clinical trial in patients with 
advanced liver cancers to evaluate its safety 
(NCT01829971). However, although considerable progresses 
have been made in this field, the clinical development of 
such strategies is still facing major hurdles of inefficient 
delivery, biodistribution and biostability [28].  
Based on our study, we proposed that miRNA functional 
approach may facilitate the identification of new relevant 
therapeutic targets, effective drug combinations, and 
eventually enable the proposition of new clinical trials. 
Indeed, we demonstrated that a BH3-mimetic molecule 
(ABT-737) binding and neutralizing Bcl-xL in combination 
with an anti-EGFR monoclonal antibody (cetuximab) or 
EGFR TKIs (erlotinib and gefitinib) mimic the apoptotic 
effect of miR-491-5p in IGROV1-R10 cells (Figure 1b), 
whereas each drug alone had no obvious effect. This 
observation is of importance in the context of ovarian 
carcinoma because to date, EGFR-directed therapies were 
used as single agents and have yielded disappointing results. 
EGFR inhibitors are widely used in clinical practice for the 
treatment of colorectal and non-small cell lung cancer [29] and 
Navitoclax (ABT-263, the orally bioavailable analogue of 
ABT-737 used in clinical trial) presents some activity in 
haematological and solid cancers [30], both molecules are 
therefore already available for a clinical use. Consequently, 
EGFR inhibitors in combination with Navitoclax would be a 
feasible and interesting way to explore in ovarian carcinoma. 
Accordingly, combination of Navitoclax with targeted 
therapies could be efficient for the treatment of various solid 
tumors as suggested by recent preclinical studies. In addition, 
although the development of direct Mcl-1 inhibitors is 
currently an active research field, these molecules are still 
dramatically lacking for clinical application. Therefore, 
BIM-inducing strategies, as observed with EGFR inhibitors, 
may represent an alternative interesting way to inhibit Mcl-1. 
Our study also demonstrated that some downstream 
alterations triggering constitutive activation of AKT and 
MAPK signaling pathways abolish the effect of EGFR 
inhibitors as observed in SKOV3 cells. In this context, the 
use of specific inhibitors of AKT and MAPK will lead to 
BIM accumulation and its desequestration by a BH3-mimetic 
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molecule will lead to cell death. Accordingly, it was shown 
in our team that the combination of BEZ-235 (a dual 
PI3K/mTOR inhibitor) and CI-1040 (a MAPK pathway 
inhibitor) with ABT-737 led to apoptosis of SKOV3 
chemoresistant cancer cell line [31]. Importantly, in both 
cancer cell lines, BH3-mimetic molecules are useful to 
sensitize ovarian carcinoma cells to BIM induction through 
the inhibition of EGFR signaling pathways. As these results 
strengthen the relevance of our approach for the design of 
innovative therapeutic strategies, an obvious limitation is the 
availability of clinically useable drugs targeting identified 
proteins and/or pathways. However, the screening of 
chemical libraries remains a valid tool for the identification 
of targeted inhibitors and the design of new clinically 
developable drugs. 
In summary, we are convinced that the precise 
characterization of selected miRNAs target networks may 
provide new insights of the regulatory events involved in 
cancer cells survival, and therefore suggest combinatorial 
drug action. Recently, an interesting study integrating 
molecular and phenotypic data to understand and target 
disease effectively has been described to ‘‘harness the 
immense power of systems biology to identify therapeutic 
strategies against cancer” [32]. The availability of an 
increasing number of molecules designed for targeted 
therapies might provide clinically useable tools to mimic the 
effect of miRNAs, in the absence of a safe and reliable way 
to directly use miRNAs into clinics. In addition, our strategy 
might help to characterize in a detailed and comprehensive 
way the regulatory networks of ovarian cancer cells. If 
proven successful, our strategy could be easily applied in 
other cancerous pathologies. The age of “miRNA-based 
network medicine” has clearly begun… 
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